510(k) Report

FDA applicant

Eps Bio Technology Corp.

Hsinchu, TW25 decisions2005–20261 recall

FDA records 25 decisions for Eps Bio Technology Corp. (Hsinchu, TW) from 2005 to 2026: 25 510(k) clearances. Most are in product codes NBW (System, Test, Blood Glucose, Over The Counter) and LFR (Glucose Dehydrogenase, Glucose). Since 2016 its 510(k)s took a median of 230 days from receipt to decision, against 179 for FDA’s reviews in the same codes and years. Its devices cite 9 predicates, 5 of them its own earlier devices. 1 recall is linked to its devices.

FDA’s records also spell it “EPS Bio Technology Corp.”.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, clinical chemistry panel, where it files most

How often FDA has decided Eps Bio Technology Corp.’s devices, and how often a recall has named them.

FDA decisions per year

1in 2021

2007: 12008: 12009: 52010: 22011: 52012: 22014: 32018: 12019: 12021: 12026 (partial year): 1
2007high 5 (2009) · low 0 (2013)2026

2026 so far, outlined.

Recalls per year

1in 2009

2009: 1
2007high 1 (2009) · low 0 (2007)2026

Class I Class II/III not classified

FIG. 1 — Eps Bio Technology Corp. by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Eps Bio Technology Corp.’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report